Tenax Therapeutics (TENX) Accounts Payables (2011 - 2026)
Tenax Therapeutics (TENX) reported Accounts Payables of $6.3 million for Q1 2026, up 245.08% on a YoY basis from $1.8 million in Q1 2025, and up 5.05% sequentially from $6.0 million in Q4 2025.
Tenax Therapeutics (TENX) Accounts Payables (2011 - 2026) Analysis & Trends
Tenax Therapeutics (TENX) has 15 years of Accounts Payables data on file, last reported at $6.3 million in Q1 2026.
- For the quarter ending Q1 2026, Accounts Payables rose 245.08% year-over-year to $6.3 million; the trailing twelve-month figure through Mar 2026 stood at $6.3 million (up 245.08% YoY), and the FY2025 full-year result was $6.0 million, up 91.35% from the prior year.
- Accounts Payables grew to $6.3 million in Q1 2026, from $6.0 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $6.3 million in Q1 2026 to a low of $134787.0 in Q3 2023.
- A 5-year average of $1.9 million and a median of $919384.0 in 2022 frame the typical range for Accounts Payables.
- Across the five-year window, Accounts Payables slumped 76.08% in 2023 and jumped 625.25% in 2024, its largest moves.
- Tracing TENX's Accounts Payables over 5 years: stood at $775045.0 in 2022, then surged by 167.47% to $2.1 million in 2023, then soared by 52.29% to $3.2 million in 2024, then soared by 91.35% to $6.0 million in 2025, then climbed by 5.05% to $6.3 million in 2026.
- Business Quant data shows TENX's Accounts Payables at $6.3 million in Q1 2026, $6.0 million in Q4 2025, and $5.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 10.62 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 423.55 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 694,346.76 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 80.54 Mn |
| 10 | Tenax Therapeutics | 67,856.40 | 67,856.40 | - | 6.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.35 Mn |
| Dec 31, 2025 | 6.04 Mn |
| Sep 30, 2025 | 5.61 Mn |
| Jun 30, 2025 | 562,000.00 |
| Mar 31, 2025 | 1.84 Mn |
| Dec 31, 2024 | 3.16 Mn |
| Sep 30, 2024 | 977,545.00 |
| Jun 30, 2024 | 592,379.00 |
| Mar 31, 2024 | 536,443.00 |
| Dec 31, 2023 | 2.07 Mn |
| Sep 30, 2023 | 134,787.00 |
| Jun 30, 2023 | 271,633.00 |
| Mar 31, 2023 | 307,922.00 |
| Dec 31, 2022 | 775,045.00 |
| Sep 30, 2022 | 265,407.00 |
| Jun 30, 2022 | 919,384.00 |
| Mar 31, 2022 | 1.29 Mn |
| Dec 31, 2021 | 859,638.00 |
| Sep 30, 2021 | 776,247.00 |
| Jun 30, 2021 | 791,947.00 |